Haemonetics (HAE) Asset Writedowns and Impairment (2013 - 2026)

Haemonetics' Asset Writedowns and Impairment history runs 13 years deep, the most recent figure standing at $77.2 million for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $77.2 million in Q1 2026; TTM through Mar 2026 was $95.1 million, a N/A change from a year earlier, with the FY2026 full-year figure at $86.5 million, up 3519.66% from the prior year.
• Asset Writedowns and Impairment advanced to $77.2 million in Q1 2026 per HAE's latest filing, from $9.3 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $77.2 million in Q1 2026 and bottomed at $94000.0 in Q3 2022.
• The 4-year median for Asset Writedowns and Impairment is $5.7 million (2022), against an average of $16.4 million.
• Across the five-year window, Asset Writedowns and Impairment sank 98.17% in 2022 and slumped 81.74% in 2023, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $94000.0 in 2022, then jumped by 445.74% to $513000.0 in 2023, then surged by 1712.87% to $9.3 million in 2025, then soared by 730.6% to $77.2 million in 2026.
• Per Business Quant, the three latest HAE Asset Writedowns and Impairment figures stand at $77.2 million (Q1 2026), $9.3 million (Q4 2025), and $8.6 million (Q3 2025).